Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
35.91-0.50 (-1.37%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close36.41
Bid35.00 x 14900
Ask37.88 x 1000
Day's Range35.55 - 36.38
52wk Range10.82 - 41.72
1y Target EstN/A
Market Cap1.19B
P/E Ratio (ttm)-11.31
Avg Vol (3m)1,135,800
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Barrons.com10 days ago

    [$$] Aerie Stock Hits High, Holder Sells $2 Million

    Entities controlled by Foresite Capital sold 50,000 shares of Aerie Pharmaceuticals (AERI) for $2,016,995, or an average of $40.34 a share, on Oct. 6. Two weeks earlier, the biotech announced a successful Phase 3 trial for its glaucoma treatment candidate, Roclatan, sending the stock on a multi-session rally. Foresite’s indirectly held stake in Aerie had topped the 10% mark in late July, making the private-equity firm a reporting entity subject to regulatory filings.

  • Benzinga17 days ago

    Clearing Up Misconceptions Surrounding Aerie Pharmaceuticals

    Cantor Fitzgerald reiterated its Buy rating and $50 price target on Aerie Pharmaceuticals Inc (NASDAQ: AERI ), as the company provided new clinical data to clear up residual misconceptions and uncertainties ...

  • 6 Best Performing Drug Stocks of September
    Zacks20 days ago

    6 Best Performing Drug Stocks of September

    These 6 pharma and biotech stocks had an impressive run in September thanks to acquisition announcements, positive clinical trial announcements and FDA approvals.